Concepedia

Eric Masson

EM

Statistics

Publications

70

Citations

4.3K

H-Index

33

Active since

1981

Affiliations

Ohio University(Current)

Novartis (United States)

École Polytechnique Fédérale de Lausanne

The University of Texas MD Anderson Cancer Center

Novartis (Germany)

Eric Masson is an author at Ohio University specializing in engineering, chemistry, and medicine.

ORCID

Top concepts

Publications per year

1981–2023

70

Publications

70

Cucurbituril chemistry: a tale of supramolecular success

Eric Masson, Xiaoxi Ling, Roymon Joseph et al. · RSC Advances · 2011 · 925 citations

, , +9

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis J. Giles, Thomas Fischer, Jörge E. Cortes et al. · Clinical Cancer Research · 2006 · 314 citations

Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer

Anne Thomas, Bruno Morgan, Mark A. Horsfield et al. · Journal of Clinical Oncology · 2005 · 225 citations

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Eric Masson, Mary V. Relling, Timothy W. Synold et al. · Journal of Clinical Investigation · 1996 · 207 citations · Full text

, , +18

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

K. Mross, Joachim Drevs, M Müller et al. · European Journal of Cancer · 2005 · 166 citations · Full text

, , +9

Rows per page

1–5 of 70